Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 3-year extension of subcutaneous secukinumab in active lupus nephritis
2021-005772-19Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in lupus nephritis (LN), sponsored by Novartis. Primary endpoint: Complete Renal Response (CRR). Started Apr 2022; status: terminated.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2021-005772-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005772-19.